Anti-PAN TEAD antibody

• IHC-P

Supplier Data

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-PAN TEAD antibody (AB97460)

ab97460, at 1/500 dilution, staining PAN TEAD in a paraffin-embedded SW480 (human) xenograft by Immunohistochemical analysis

• ICC/IF

Supplier Data

Immunocytochemistry/ Immunofluorescence - Anti-PAN TEAD antibody (AB97460)

Immunofluorescence analysis of HeLa cells fixed in 4% paraformaldehyde at RT for 15 min labelling TEAD4 protein at nucleus using ab97460 at a 1/1000 dilution (Green). phalloidin, a cytoskeleton marker, was stained at a 1/200 dilution (Red). Scale bar = 10 µm

• WB

Supplier Data

Western blot - Anti-PAN TEAD antibody (AB97460)

Samples were separated by 10% SDS-PAGE. The signal was developed with Trident ECL plus Enhanced.

All lanes:

Western blot - Anti-PAN TEAD antibody (ab97460) at 1/2000 dilution

Lane 1:

HepG2 whole cell lysates at 30 µg

Lane 2:

HepG2 nuclear extracts at 30 µg

Secondary

All lanes:

HRP conjugated anti rabbit IgG antibody

Predicted band size: 48 kDa

true

• WB

Lab

Western blot - Anti-PAN TEAD antibody (AB97460)

Blocking and diluting buffer : 5% NFDM /TBST

All lanes:

Western blot - Anti-PAN TEAD antibody (ab97460) at 1/1000 dilution

Lane 1:

TEAD1 Human Recombinant Protein at 20 µg

Lane 2:

TEAD2 Human Recombinant Protein at 20 µg

Lane 3:

TEAD3 Human Recombinant Protein at 20 µg

Lane 4:

TEAD4 Human Recombinant Protein at 20 µg

Secondary

All lanes:

Western blot - Goat Anti-Rabbit IgG H&L (HRP) (<a href='/en-us/products/secondary-antibodies/goat-rabbit-igg-h-l-hrp-ab97051'>ab97051</a>) at 1/20000 dilution

false

Exposure time: 180s

• IHC

CiteAb

Immunohistochemistry - Anti-PAN TEAD antibody (AB97460)

Immunohistochemistry using Anti-PAN TEAD antibodyAnti-PAN TEAD antibody, ab97460. Publication image from Chen, Y. et al., 2017, Nat Commun, 28474680. Legend direct from paper.

YAP expression is associated with global O-GlcNAcylation in liver cancer tissues and established liver cancer cell lines.(a–c) TMA of YAP, Ki67, O-GlcNAc, CTGF and TEAD. IHC images of TMA stained with anti-YAP, anti-Ki67, anti-CTGF, anti-TEAD and anti-O-GlcNAc antibody, (a). Enlarged IHC images of YAP and O-GlcNAc staining from the TMA (b). The data were analysed using a chi-square test (c). (d–f) O-GlcNAc and YAP expression in liver cancer and established cell lines. Western blots of O-GlcNAc, TEAD, p-YAP and YAP in liver cancer and adjacent normal liver tissues. The levels of p-YAP were normalized to those of YAP. In addition, the levels of O-GlcNAc and YAP were normalized to those of GAPDH. The levels of the #1 sample of liver cancer were arbitrarily set to 100% (d). Representative images of IHC staining of YAP, TEAD and O-GlcNAc in liver cancer and adjacent normal liver tissues. Scale bar, 500 µM. The liver cancer and normal liver tissue samples are paired (e). YAP and TEAD expression and O-GlcNAc levels in established hepatocyte (THLE-3 and HL-7702) and the indicated liver cancer cell lines detected by IHC and WB, respectively. The levels of YAP and of O-GlcNAc were normalized to those of GAPDH, and the levels of the THLE-3 cells were arbitrarily set to 100% (f). The data are shown as the means+s.d. from three independent experiments (including WB). **P<0.01 indicates statistical significance. Data in c,d,f were analysed using a χ2 test, two-way and one-way ANOVA tests, respectively.

• IHC

CiteAb

Immunohistochemistry - Anti-PAN TEAD antibody (AB97460)

Immunohistochemistry using Anti-PAN TEAD antibodyAnti-PAN TEAD antibody, ab97460. Publication image from Chen, Y. et al., 2017, Nat Commun, 28474680. Legend direct from paper.

YAP expression is associated with global O-GlcNAcylation in liver cancer tissues and established liver cancer cell lines.(a–c) TMA of YAP, Ki67, O-GlcNAc, CTGF and TEAD. IHC images of TMA stained with anti-YAP, anti-Ki67, anti-CTGF, anti-TEAD and anti-O-GlcNAc antibody, (a). Enlarged IHC images of YAP and O-GlcNAc staining from the TMA (b). The data were analysed using a chi-square test (c). (d–f) O-GlcNAc and YAP expression in liver cancer and established cell lines. Western blots of O-GlcNAc, TEAD, p-YAP and YAP in liver cancer and adjacent normal liver tissues. The levels of p-YAP were normalized to those of YAP. In addition, the levels of O-GlcNAc and YAP were normalized to those of GAPDH. The levels of the #1 sample of liver cancer were arbitrarily set to 100% (d). Representative images of IHC staining of YAP, TEAD and O-GlcNAc in liver cancer and adjacent normal liver tissues. Scale bar, 500 µM. The liver cancer and normal liver tissue samples are paired (e). YAP and TEAD expression and O-GlcNAc levels in established hepatocyte (THLE-3 and HL-7702) and the indicated liver cancer cell lines detected by IHC and WB, respectively. The levels of YAP and of O-GlcNAc were normalized to those of GAPDH, and the levels of the THLE-3 cells were arbitrarily set to 100% (f). The data are shown as the means+s.d. from three independent experiments (including WB). **P<0.01 indicates statistical significance. Data in c,d,f were analysed using a χ2 test, two-way and one-way ANOVA tests, respectively.

• IHC

CiteAb

Immunohistochemistry - Anti-PAN TEAD antibody (AB97460)

Immunohistochemistry using Anti-PAN TEAD antibodyAnti-PAN TEAD antibody, ab97460. Publication image from Chen, Y. et al., 2017, Nat Commun, 28474680. Legend direct from paper.

YAP expression is associated with global O-GlcNAcylation in liver cancer tissues and established liver cancer cell lines.(a–c) TMA of YAP, Ki67, O-GlcNAc, CTGF and TEAD. IHC images of TMA stained with anti-YAP, anti-Ki67, anti-CTGF, anti-TEAD and anti-O-GlcNAc antibody, (a). Enlarged IHC images of YAP and O-GlcNAc staining from the TMA (b). The data were analysed using a chi-square test (c). (d–f) O-GlcNAc and YAP expression in liver cancer and established cell lines. Western blots of O-GlcNAc, TEAD, p-YAP and YAP in liver cancer and adjacent normal liver tissues. The levels of p-YAP were normalized to those of YAP. In addition, the levels of O-GlcNAc and YAP were normalized to those of GAPDH. The levels of the #1 sample of liver cancer were arbitrarily set to 100% (d). Representative images of IHC staining of YAP, TEAD and O-GlcNAc in liver cancer and adjacent normal liver tissues. Scale bar, 500 µM. The liver cancer and normal liver tissue samples are paired (e). YAP and TEAD expression and O-GlcNAc levels in established hepatocyte (THLE-3 and HL-7702) and the indicated liver cancer cell lines detected by IHC and WB, respectively. The levels of YAP and of O-GlcNAc were normalized to those of GAPDH, and the levels of the THLE-3 cells were arbitrarily set to 100% (f). The data are shown as the means+s.d. from three independent experiments (including WB). **P<0.01 indicates statistical significance. Data in c,d,f were analysed using a χ2 test, two-way and one-way ANOVA tests, respectively.